Abstract 2068P
Background
Sexual dysfunction is a frequently seen late effect in patients treated for testicular germ cell tumour (TGCT). Therefore, monitoring of sexual dysfunction is essential. The Utrecht Symptom Diary (USD) helps monitoring cancer symptoms, but items regarding sexuality are missing. Adding these symptoms may provide a better tailored tool, enhance monitoring of late effects on sexuality, and might help to address this topic. Therefore, the aim of this study was to explore perspectives and concerns on late effects regarding sexuality among adolescents and young adults (AYAs) being treated for TGCT to adapt the USD to make it suitable for follow-up care for these patients.
Methods
Individual, semi-structured interviews were conducted with thirteen AYAs from one centre of expertise for TGCT in the Netherlands. Patients were purposively sampled and using maximum variation. Data was analysed using Braun and Clark’s thematic analysis.
Results
Interviews revealed seven overarching themes which interact and overlap: fulfilment to have children, rediscover sexuality, insecurity about sexual performance, acceptance of physical change, loss of masculinity, burden on relationship, and need to talk about sexuality. Concerns related to the fulfilment to have children seems to play a major role.
Conclusions
Results help to better understand these men’s thoughts and experiences related to late effects regarding sexuality and gives healthcare professionals the opportunity to act on these topics by discussing it in the consulting room. Partner involvement seems beneficial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06